Literature DB >> 29531483

Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis.

Tomoo Kishaba1, Yuichiro Nei1, Masashi Momose1, Hiroaki Nagano1, Shin Yamashiro1.   

Abstract

OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is the most common parenchymal lung disease. Patients with IPF sometimes develop acute exacerbation (AE), which predicts a poor prognosis. To evaluate the predictors of 90-day mortality of AE in patients with IPF based on the new 2016 criteria.
MATERIALS AND METHODS: Sixty-five patients with AE were studied retrospectively between January 2001 and December 2016 at Okinawa Chubu Hospital.
RESULTS: The mean age of the patients was 74 years, with 40 (61.5%) men and 25 (38.5%) women. Among our cohort, 37 were current or ex-smokers, with a mean exposure of 32.4 pack-years. The mean grade of the modified Medical Research Council breathlessness scale was 2.8, and the mean duration of dyspnea prior to admission was 6.5 days. Clubbed fingernails were present in 29% of patients. Triggered AE occurred in 12 (18%) of patients. Patients with triggered AE had more extensive ground-glass opacity and higher consolidation scores than the idiopathic AE group (7.3 vs. 4.2, p=0.01). The triggered group had shorter survival than the idiopathic group (1.4 vs. 11.4 months, p=0.094). Serum lactate dehydrogenase (LDH), ΔLDH, and the ratio of partial pressure of oxygen to the fraction of inspiratory oxygen ratio were strong predictors of 90-day mortality. Hazard ratios were 1.003 (p=0.004), 1.004 (p=0.02), and 0.994 (p=0.010), respectively.
CONCLUSION: Compared with idiopathic AE, triggered AE in patients with IPF had more extensive infiltration and tended toward shorter survival. Serial trends of serum LDH >2 weeks can help predict prognosis of AE in patients with IPF.

Entities:  

Keywords:  Predictors; lactate dehydrogenase; mortality; partial pressure of oxygen/fraction of inspiratory oxygen ratio; triggered

Year:  2018        PMID: 29531483      PMCID: PMC5843459          DOI: 10.5152/eurasianjmed.2018.17330

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  31 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials.

Authors:  C P Atkins; Y K Loke; A M Wilson
Journal:  Respir Med       Date:  2013-11-19       Impact factor: 3.415

3.  Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure.

Authors:  J B Stern; H Mal; O Groussard; O Brugière; A Marceau; G Jebrak; M Fournier
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

Review 4.  Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.

Authors:  Nobuhisa Ishikawa; Noboru Hattori; Akihito Yokoyama; Nobuoki Kohno
Journal:  Respir Investig       Date:  2012-03-08

Review 5.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

6.  Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Authors:  Ganesh Raghu; Athol U Wells; Andrew G Nicholson; Luca Richeldi; Kevin R Flaherty; Florence Le Maulf; Susanne Stowasser; Rozsa Schlenker-Herceg; David M Hansell
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

7.  Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival.

Authors:  Hiromitsu Sumikawa; Takeshi Johkoh; Thomas V Colby; Kazuya Ichikado; Moritaka Suga; Hiroyuki Taniguchi; Yasuhiro Kondoh; Takashi Ogura; Hiroaki Arakawa; Kiminori Fujimoto; Atsuo Inoue; Naoki Mihara; Osamu Honda; Noriyuki Tomiyama; Hironobu Nakamura; Nestor L Müller
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

8.  Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis.

Authors:  Tomoo Kishaba; Hitoshi Tamaki; Yousuke Shimaoka; Hajime Fukuyama; Shin Yamashiro
Journal:  Lung       Date:  2013-11-13       Impact factor: 2.584

9.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

10.  Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.

Authors:  Kosuke Hamai; Hiroshi Iwamoto; Nobuhisa Ishikawa; Yasushi Horimasu; Takeshi Masuda; Shintaro Miyamoto; Taku Nakashima; Shinichiro Ohshimo; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori; Nobuoki Kohno
Journal:  Dis Markers       Date:  2016-05-17       Impact factor: 3.434

View more
  4 in total

1.  Inflammatory indices obtained from routine blood tests show an inflammatory state associated with disease progression in engineered stone silicosis patients.

Authors:  Alejandro García-Núñez; Gema Jiménez-Gómez; Antonio Hidalgo-Molina; Juan Antonio Córdoba-Doña; Antonio León-Jiménez; Antonio Campos-Caro
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

2.  Impact of the revised definition on incidence and outcomes of acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Jung-Wan Yoo; Jehun Kim; Jin Woo Song
Journal:  Sci Rep       Date:  2022-05-25       Impact factor: 4.996

3.  Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study.

Authors:  Masatoshi Yamazoe; Hiromi Tomioka
Journal:  BMJ Open Respir Res       Date:  2018-10-09

4.  Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMJ Open       Date:  2020-06-15       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.